Maiwei Biotechnology: It is expected that the H shares will be listed on the Hong Kong Stock Exchange on April 28th.

On the morning of April 20th, Mayway Biotech announced that the company is conducting the issuance of overseas listed foreign shares and listing on the main board of the Hong Kong Stock Exchange. On April 20, 2026, the company published and distributed the prospectus for the issuance and listing of H shares on the Hong Kong Stock Exchange website in accordance with relevant regulations. The company's total number of H shares for global offering this time is 47.1302 million shares, of which, about 10% are preliminarily arranged for public offering in Hong Kong (4.7132 million shares), and about 90% for international offering (42.417 million shares). The preliminary price range for this H share issuance is set at 27.64 Hong Kong dollars to 30.71 Hong Kong dollars. The public offering of H shares in Hong Kong began on April 20, 2026, and is expected to end on April 23, 2026, with the issuance price to be announced by April 24, 2026. The H shares issued this time are expected to be listed and traded on the Hong Kong Stock Exchange on April 28, 2026.